Allogene Therapeutics (ALLO) Short Interest Ratio & Short Volume $1.08 -0.15 (-12.20%) Closing price 04:00 PM EasternExtended Trading$1.09 +0.01 (+0.93%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Allogene Therapeutics Short Interest DataAllogene Therapeutics (ALLO) has a short interest of 25.93 million shares. This marks a -2.41% decrease in short interest from the previous month. The short interest ratio (days to cover) is 7.8, indicating that it would take 7.8 days of the average trading volume of 4.33 million shares to cover all short positions.Current Short Interest25,930,000 sharesPrevious Short Interest26,570,000 sharesChange Vs. Previous Month-2.41%Dollar Volume Sold Short$32.15 millionShort Interest Ratio7.8 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares218,731,000 sharesPercentage of Shares Shorted11.85%Today's Trading Volume19,087,454 sharesAverage Trading Volume4,330,540 sharesToday's Volume Vs. Average441% Short Selling Allogene Therapeutics? Sign up to receive the latest short interest report for Allogene Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartALLO Short Interest Over TimeALLO Days to Cover Over TimeALLO Percentage of Float Shorted Over Time Allogene Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202525,930,000 shares $32.15 million -2.4%N/A7.8 $1.24 6/30/202526,570,000 shares $30.02 million +2.0%14.0%8.1 $1.13 6/15/202526,040,000 shares $34.89 million +6.0%13.7%8.6 $1.34 5/31/202524,570,000 shares $28.62 million -10.2%15.5%7.4 $1.17 5/15/202527,360,000 shares $29.82 million -9.2%17.2%7.9 $1.09 4/30/202530,130,000 shares $50.62 million -8.2%N/A5.5 $1.68 4/15/202532,810,000 shares $47.90 million -5.6%20.7%6.3 $1.46 3/31/202534,760,000 shares $50.75 million -8.6%24.9%6.5 $1.46 3/15/202538,010,000 shares $73.74 million -2.8%27.2%7.1 $1.94 2/28/202539,100,000 shares $76.25 million +16.2%29.1%7.6 $1.95 Get the Latest News and Ratings for ALLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202533,660,000 shares $68.67 million +5.0%25.0%6.7 $2.04 1/31/202532,050,000 shares $57.69 million -0.9%22.8%11.7 $1.80 1/15/202532,350,000 shares $60.49 million +4.7%N/A12 $1.87 12/31/202430,910,000 shares $65.84 million -4.5%N/A12.4 $2.13 12/15/202432,370,000 shares $61.18 million +3.9%N/A14.1 $1.89 11/30/202431,170,000 shares $77.30 million -11.1%N/A13.8 $2.48 11/15/202435,050,000 shares $79.56 million -5.4%N/A16.2 $2.27 10/31/202437,040,000 shares $94.64 million -5.8%26.7%18.7 $2.56 10/15/202439,320,000 shares $106.56 million +2.1%28.5%21.7 $2.71 9/30/202438,510,000 shares $107.83 million -1.7%28.2%18.3 $2.80 9/15/202439,190,000 shares $116.00 million +0.6%28.7%17 $2.96 8/31/202438,940,000 shares $102.41 million -0.7%28.5%15.8 $2.63 8/15/202439,230,000 shares $90.23 million +3.9%28.7%14.5 $2.30 7/31/202437,750,000 shares $110.99 million -12.7%27.6%12.9 $2.94 7/15/202443,230,000 shares $128.83 million +4.5%31.6%14.7 $2.98 6/30/202441,380,000 shares $96.42 million -4.4%30.3%15.3 $2.33 6/15/202443,280,000 shares $101.71 million +6.7%31.7%17.1 $2.35 5/31/202440,570,000 shares $101.43 million +11.4%33.5%16.2 $2.50 5/15/202436,430,000 shares $108.56 million +7.6%30.1%15.7 $2.98 4/30/202433,870,000 shares $93.48 million +8.0%32.0%15.5 $2.76 4/15/202431,360,000 shares $111.33 million +2.4%30.0%13.9 $3.55 3/31/202430,620,000 shares $136.87 million +10.3%29.3%11.7 $4.47 3/15/202427,750,000 shares $129.32 million +11.0%26.6%10 $4.66 2/29/202425,010,000 shares $122.80 million +6.7%24.1%8.3 $4.91 2/15/202423,450,000 shares $116.31 million +1.6%22.6%7.7 $4.96 1/31/202423,090,000 shares $81.28 million -23.6%22.2%7.4 $3.52 1/15/202430,210,000 shares $97.28 million -3.5%28.5%10.3 $3.22 12/31/202331,320,000 shares $100.54 million -6.7%29.6%11.9 $3.21 12/15/202333,550,000 shares $90.92 million +5.3%31.7%14.3 $2.71 11/30/202331,860,000 shares $74.87 million -1.5%30.1%16.8 $2.35Leaked Gov’t Memo Reveals $100 Trillion Deadline (Ad)Only Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.Click here now to discover the full story and how to stake your claim before this land rush goes ful 11/15/202332,340,000 shares $87.96 million -5.0%30.6%18.9 $2.72 10/31/202334,030,000 shares $95.96 million +10.7%32.2%22 $2.82 10/15/202330,730,000 shares $98.03 million -10.0%29.2%18 $3.19 9/30/202334,130,000 shares $108.19 million +2.1%32.2%19 $3.17 9/15/202333,420,000 shares $130.00 million +4.1%31.5%16.2 $3.89 8/31/202332,110,000 shares $124.91 million -2.0%30.3%12.4 $3.89 8/15/202332,770,000 shares $133.70 million -13.6%30.9%12.5 $4.08 7/31/202337,910,000 shares $188.03 million -8.1%39.4%14.3 $4.96 7/15/202341,260,000 shares $204.65 million +8.1%53.9%15.3 $4.96 6/30/202338,180,000 shares $189.75 million +1.7%49.9%14.1 $4.97 6/15/202337,560,000 shares $186.67 million -6.2%49.1%15.1 $4.97 5/31/202340,030,000 shares $210.16 million -1.4%52.1%20.4 $5.25 5/15/202340,590,000 shares $273.58 million -0.2%52.8%19.6 $6.74 4/30/202340,650,000 shares $220.73 million -1.4%53.3%20.3 $5.43 4/15/202341,220,000 shares $205.69 million +0.5%54.5%22.2 $4.99 3/31/202341,010,000 shares $202.59 million +3.0%54.3%22.5 $4.94 3/15/202339,800,000 shares $225.27 million +8.0%49.6%20.9 $5.66 2/28/202336,860,000 shares $234.06 million +4.9%46.0%19.4 $6.35 2/15/202335,140,000 shares $254.06 million +2.1%44.0%18.4 $7.23 1/31/202334,410,000 shares $265.65 million +0.7%43.1%18 $7.72 1/15/202334,160,000 shares $241.17 million +2.2%42.7%18.1 $7.06 12/30/202233,430,000 shares $210.27 million +9.5%41.8%18 $6.29 12/15/202230,530,000 shares $216.15 million +0.2%38.2%16 $7.08 11/30/202230,470,000 shares $300.43 million -3.2%38.1%16.5 $9.86 11/15/202231,460,000 shares $311.45 million +1.6%39.3%18.2 $9.90 10/31/202230,960,000 shares $318.89 million +3.0%39.3%18.3 $10.30 10/15/202230,050,000 shares $305.91 million +8.9%38.3%18 $10.18 9/30/202227,590,000 shares $297.97 million +24.2%35.2%16 $10.80 9/15/202222,220,000 shares $311.08 million +0.9%28.3%12.8 $14.00 8/31/202222,020,000 shares $301.89 million -2.4%28.1%12 $13.71 8/15/202222,570,000 shares $390.01 million +0.8%28.8%11.6 $17.28 7/31/202222,400,000 shares $290.75 million -0.1%28.6%10.9 $12.98 7/15/202222,430,000 shares $287.33 million -0.3%28.6%10.2 $12.81 6/30/202222,490,000 shares $256.39 million +2.0%28.5%10.5 $11.40 6/15/202222,060,000 shares $212.22 million +9.5%28.0%10.8 $9.62 5/31/202220,150,000 shares $159.79 million +13.9%25.7%10.8 $7.93 5/15/202217,690,000 shares $127.90 million -0.4%22.5%9.6 $7.23 4/30/202217,760,000 shares $148.30 million -1.7%24.3%10.4 $8.35 4/15/202218,060,000 shares $149.00 million +18.6%24.8%11.4 $8.25 3/31/202215,230,000 shares $138.75 million +4.8%16.1%8.9 $9.11 3/15/202214,540,000 shares $113.41 million +18.7%19.8%8.6 $7.80 2/28/202212,250,000 shares $112.09 million +16.9%16.7%7.5 $9.15 2/15/202210,480,000 shares $106.79 million +10.0%14.3%6.8 $10.19 1/31/20229,530,000 shares $109.12 million +5.1%14.3%6.6 $11.45 1/15/20229,070,000 shares $120.45 million +19.7%13.6%6.2 $13.28 12/31/20217,580,000 shares $113.09 million +34.9%11.4%4.1 $14.92 12/15/20215,620,000 shares $86.38 million +4.7%8.4%2.7 $15.37 11/30/20215,370,000 shares $99.29 million -5.3%8.1%2.9 $18.49 11/15/20215,670,000 shares $106.99 million +19.6%8.5%3.1 $18.87 10/29/20214,740,000 shares $81.72 million +0.2%7.1%2.6 $17.24Leaked Gov’t Memo Reveals $100 Trillion Deadline (Ad)Only Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.Click here now to discover the full story and how to stake your claim before this land rush goes ful 10/15/20214,730,000 shares $77.95 million -40.7%7.1%2.8 $16.48 9/30/20217,980,000 shares $205.09 million +1.7%12.0%6.7 $25.70 9/15/20217,850,000 shares $196.25 million -6.0%11.8%9.5 $25.00 8/31/20218,350,000 shares $199.15 million -0.4%11.7%9.4 $23.85 8/13/20218,380,000 shares $179.67 million -9.6%11.7%7.5 $21.44 7/30/20219,270,000 shares $203.48 million -2.2%13.0%7.1 $21.95 7/15/20219,480,000 shares $211.88 million +0.2%13.3%7.1 $22.35 6/30/20219,460,000 shares $246.72 million +15.5%13.3%7 $26.08 6/15/20218,190,000 shares $205.00 million +3.0%11.5%7 $25.03 5/28/20217,950,000 shares $204.32 million -3.4%11.3%6.8 $25.70 5/14/20218,230,000 shares $221.72 million +13.5%11.6%7.8 $26.94 4/30/20217,250,000 shares $231.86 million -12.7%10.2%8.5 $31.98 4/15/20218,300,000 shares $266.85 million -3.8%11.9%10.1 $32.15 3/31/20218,630,000 shares $288.50 million -16.1%12.4%10 $33.43 3/15/202110,290,000 shares $395.96 million -10.9%14.6%11.1 $38.48 2/26/202111,550,000 shares $378.72 million +4.2%16.5%12.4 $32.79 2/12/202111,080,000 shares $381.15 million -4.0%15.8%12.6 $34.40 1/29/202111,540,000 shares $398.25 million -15.9%16.8%12.8 $34.51 1/15/202113,720,000 shares $426.28 million +5.2%20.1%14.8 $31.07 12/31/202013,040,000 shares $347.39 million +15.7%19.1%15.4 $26.64 12/15/202011,270,000 shares $315.56 million +5.8%16.5%13.8 $28.00 11/30/202010,650,000 shares $335.69 million +0.7%15.7%14.1 $31.52 11/15/202010,580,000 shares $339.30 million +5.1%15.6%15.4 $32.07 10/30/202010,070,000 shares $358.19 million -0.5%14.9%15.5 $35.57 10/15/202010,120,000 shares $436.88 million -2.3%15.0%17.2 $43.17 9/30/202010,360,000 shares $390.68 million +1.5%15.4%17.7 $37.71 9/15/202010,210,000 shares $363.58 million -5.0%15.1%16.3 $35.61 8/31/202010,750,000 shares $383.24 million +0.6%15.9%16.6 $35.65 8/14/202010,690,000 shares $394.78 million -2.8%15.9%11.9 $36.93 ALLO Short Interest - Frequently Asked Questions What is Allogene Therapeutics' current short interest? Short interest is the volume of Allogene Therapeutics shares that have been sold short but have not yet been closed out or covered. As of July 15th, investors have sold 25,930,000 shares of ALLO short. Learn More on Allogene Therapeutics' current short interest. What is a good short interest ratio for Allogene Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALLO shares currently have a short interest ratio of 8.0. Learn More on Allogene Therapeutics's short interest ratio. Which institutional investors are shorting Allogene Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Allogene Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Allogene Therapeutics' short interest increasing or decreasing? Allogene Therapeutics saw a drop in short interest in July. As of July 15th, there was short interest totaling 25,930,000 shares, a drop of 2.4% from the previous total of 26,570,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Allogene Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Allogene Therapeutics: Cidara Therapeutics, Inc. (12.98%), Praxis Precision Medicines, Inc. (10.65%), Enliven Therapeutics, Inc. (14.29%), Avadel Pharmaceuticals PLC. (12.72%), Ardelyx, Inc. (11.53%), Dyne Therapeutics, Inc. (11.06%), Structure Therapeutics Inc. Sponsored ADR (14.37%), GH Research PLC (6.22%), Akebia Therapeutics, Inc. (9.66%), Sana Biotechnology, Inc. (27.79%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Allogene Therapeutics stock? Short selling ALLO is an investing strategy that aims to generate trading profit from Allogene Therapeutics as its price is falling. ALLO shares are trading down $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Allogene Therapeutics? A short squeeze for Allogene Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALLO, which in turn drives the price of the stock up even further. How often is Allogene Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALLO, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies Cidara Therapeutics Short Squeeze Praxis Precision Medicines Short Squeeze Enliven Therapeutics Short Squeeze Avadel Pharmaceuticals Short Squeeze Ardelyx Short Squeeze Dyne Therapeutics Short Squeeze Structure Therapeutics Short Squeeze GH Research Short Squeeze Akebia Therapeutics Short Squeeze Sana Biotechnology Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ALLO) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto America27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLO Stock Alerts